NCT07484139 · Interventional trial
H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)
Overall registry status Recruiting
Phase 2
Conditions Head and Neck Cancer, Oral Cavity Squamous Cell Carcinoma
Delaware Valley sites
- Thomas Jefferson University · Philadelphia, PA · Philadelphia County · Not yet recruiting
First posted
Registry updated
Added to the directory